AI Analysis of 410,000 Reddit Posts Flags Possible Side Effects Missing From GLP-1 Drug Labels

An artificial-intelligence analysis of more than 410,000 Reddit posts is drawing attention to side effects that patients say they experience while taking popular GLP-1 drugs, including Ozempic and Wegovy.

The study examined posts published from May 2019 through June 2025 that mentioned semaglutide or tirzepatide. Researchers identified 67,008 users who said they had taken one of the medications. Among them, 43.5% described at least one side effect.

The most frequently reported symptoms were familiar ones: nausea, fatigue, vomiting, constipation and diarrhea. But the analysis also highlighted two categories that researchers said may not be fully captured in clinical trials or current regulatory documents: reproductive symptoms, such as irregular menstrual cycles, and temperature-related complaints, including chills and hot flashes.

That does not mean the study discovered newly proven adverse effects. The posts were written by individual users, without the clinical examinations, medical histories or comparison groups needed to determine whether a drug caused a symptom. Some people may have had an underlying condition, taken another medication or experienced a symptom unrelated to treatment.

The value of the analysis is different. It shows how machine-learning tools can sort through a volume of patient conversations that would be difficult for researchers to review manually. The software can identify recurring terms and symptom patterns, giving scientists a list of questions to investigate in more rigorous data.

That approach matters because formal clinical trials are designed to answer specific questions over defined periods. They may not capture every experience that emerges after a medication reaches a much larger and more diverse population. Online discussions, meanwhile, can reveal concerns that patients bring to one another before those concerns are systematically studied.

But Reddit is not a miniature version of the population taking these medications. People who experience troubling symptoms may be more likely to post than people who have no problems. Reddit users also differ from the broader population in age, geography and other characteristics. The researchers therefore describe the findings as signals for further study, not as estimates of how common the symptoms are among all Ozempic or Wegovy users.

Current Food and Drug Administration labeling for Wegovy already identifies gastrointestinal reactions and other established warnings. The agency’s prescribing information also distinguishes between recognized risks and information that remains uncertain. The menstrual and temperature-related complaints highlighted by the Reddit analysis should be understood in that gap: they are patient-reported patterns that may deserve investigation, not additions to the official side-effect list.

The study also combined reports involving semaglutide and tirzepatide. That means the analysis cannot by itself determine whether a particular symptom is associated with semaglutide brands such as Ozempic and Wegovy, tirzepatide products, both drug classes or factors shared by their users.

The next step is validation. Researchers could compare the online signals with electronic health records, clinical trial data, adverse-event reports and prospective studies that track symptoms before and after treatment. They would also need to examine whether reports differ by dose, age, sex, underlying medical conditions and other medicines.

For patients, the practical lesson is not to assume that every symptom discussed online is caused by a GLP-1 drug—or to dismiss a concerning symptom because it is not yet listed on a label. New or severe symptoms should be discussed with a clinician, who can assess other possible causes and determine whether treatment should change.

The broader lesson is about how drug safety may evolve. AI can help researchers listen to patients at a scale that traditional review cannot match. It can point toward overlooked questions. It cannot, on its own, answer them.